I am genuinely thrilled to join a team as accomplished as Histogen’s at this important juncture in the commercialization process.
San Diego, CA (PRWEB) October 18, 2016
Histogen, Inc., a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, today announced that Martin Latterich, Ph.D. has joined the Company as Vice President of Technical Operations.
Dr. Latterich brings a wealth of biotechnology experience from both the business and academic sectors to Histogen. In addition to ProterixBio, Inc., a company developing disease management solutions for which he currently serves as Chief Scientific Officer, Dr. Latterich’s past professional affiliations include the Salk Institute, Diversa, and Illumina. He has a track record of success in the establishment and growth of science-focused research organizations, team-building, corporate scientific leadership and external collaborations and partnerships. Dr. Latterich has authored 39 publications and one book, has served as Editor-in-Chief of Proteome Science since 2002, and has been the recipient of grant funding from organizations including the NIH, HFSP, March of Dimes, Pew Foundation, and Genome Canada.
“Dr. Latterich’s background and expertise in the development and management of research programs will be a tremendous asset as Histogen progresses its hair program through clinical trials,” said Dr. Gail Naughton, CEO and Chairman of the Board. “His guidance will also be very valuable to our joint venture programs in orthopedics and oncology, and we are excited to have him on board.”
Through Histogen’s proprietary technology process, hypoxia-induced multipotent cells naturally secrete an array of growth factors, proteins and peptides which have been shown to stimulate stem cells in the body. Histogen’s lead application, the Hair Stimulating Complex (HSC), utilizes these naturally-secreted proteins to stimulate hair growth. Safety and statistically significant hair growth have been seen in two Company-sponsored clinical trials to date, and Histogen is working towards the next stages of clinical development in the United States, and well as through partnerships in other regions.
“Histogen will transform the field of cosmetics and regenerative medicine with its innovative cell-free and cell therapeutic technologies,” said Dr. Latterich. “I am genuinely thrilled to join a team as accomplished as Histogen’s at this important juncture in the commercialization process. I look forward to contributing to the success of its commercial products as well as a plethora of future new product opportunities”.
Histogen is a regenerative medicine company developing innovative products from cells grown under simulated embryonic conditions, including low oxygen and suspension. Through this unique technology process, newborn cells are directed to naturally produce vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen's technology focuses on stimulating a patient's own stem cells by delivering a proprietary complex of multipotent human proteins that have been shown to support stem cell growth and differentiation. For more information, please visit http://www.histogen.com.